On Wednesday morning, the California pump company announced that the FDA had approved its first combo device on Sept. See the links below to the Summary of Safety and Effectiveness Data (SSED) and product labeling for more complete information on this product, its indications for use, and the basis for FDA’s approval. Wait a minute…19? We studied 68 patients from 19 to 69 years old, 35 with DM1 and 33 with DM2. In all, 111 participants (60.4% female, mean = 37.6 years, SD = 11.2) participated in a web-based survey; 40 were current CGM users, 18 were former users and 53 had no experience with CGM systems. Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. Through the offering, continuous glucose measurements will be captured by a wearable sensor and wirelessly sent to a receiver, recording readings throughout the day.
Join us for a discussion on the pros and cons of Insulin Pump Therapy (IPT). Lag times were inconsistent between devices, ranging from 0 to 32 min; area under the curve revealed a tendency for DEX to report higher total glucose exposure than GRT for the same patient. Ideally you would also consider a trial by Patients such as myself, that have pumps, but are up available to get funding from your CCG for a Continuous Glucose Monitor (CGM). Analysis of 12 month primary outcomes will begin in September 2014.